Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case.
A hypercalcemic patient with adult T-cell leukemia was treated with deoxycoformycin (DCF) in a dose of 5 mg/m2 daily for three days. Several days later, severe thrombocytopenia appeared abruptly and then microangiopathic hemolytic anemia ensued. Subsequently, renal failure and hypertension developed, and the patient died seven weeks after DCF therapy. Needle necropsy of the kidney showed glomerular damage including swelling of endothelial cells, mesangiolysis and segmental collapse. This is the second reported case of hemolytic-uremic syndrome due to DCF.
Sakai
C
C
Division of the Hematology and Chemotherapy, Chiba Cancer Center Hospital.
Takagi
T
T
Wakatsuki
S
S
Matsuzaki
O
O
D017809:Fatal Outcome; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D015458:Leukemia, T-Cell / Q000188:drug therapy*; D008875:Middle Aged; D015649:Pentostatin / Q000009:adverse effects*
D015649:Pentostatin